✦ LIBER ✦

Biochemotherapy in patients with advanced head and neck mucosal melanoma

✍ Scribed by Holly L. Bartell; Agop Y. Bedikian; Nicholas E. Papadopoulos; Tina K. Dett; Matthew T. Ballo; Jeffrey N. Myers; Patrick Hwu; Kevin B. Kim

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 139 KB
Volume: 30
Category: Article
ISSN: 1043-3074
DOI: 10.1002/hed.20910

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background.

No systemic therapy regimen has been recognized as effective for metastatic mucosal melanoma of the head and neck. We retrospectively analyzed the effectiveness of biochemotherapy in patients with advanced head and neck mucosal melanoma.

Methods.

We evaluated the medical records of 15 patients at our institution who had received various biochemotherapy regimens for advanced head and neck mucosal melanoma.

Results.

After a median follow‐up duration of 13 months, 3 patients (20%) had partial response, and 4 patients (27%) had complete response. The median time to disease progression for all 15 patients was 10 months. The median overall survival duration for all patients was 22 months.

Conclusions.

Although this was a small study, our results, especially the high complete response and overall response rates, indicate that biochemotherapy for advanced head and neck mucosal melanoma should be considered as a systemic treatment option for patients with this aggressive malignancy. © 2008 Wiley Periodicals, Inc. Head Neck, 2008

📜 SIMILAR VOLUMES

Biochemotherapy in patients with metasta

Biochemotherapy in patients with metastatic anorectal mucosal melanoma

✍ Kevin B. Kim; Angela M. Sanguino; Cynthia Hodges; Nicholas E. Papadopoulos; Omar 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 1 views

## Abstract ## BACKGROUND Patients with metastatic anorectal melanoma generally have an unfavorable prognosis, but no effective systemic therapy has been reported. ## METHODS The authors retrospectively evaluated the medical records of all patients with metastatic anorectal melanoma treated with

Planned postradiotherapy neck dissection

Planned postradiotherapy neck dissection in patients with advanced head and neck cancer

✍ Timothy S. Boyd; Paul M. Harari; Scott P. Tannehill; Marta C. Voytovich; Gregory 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 2 views

## Background: Metastatic neck nodes in patients with squamous cell carcinoma of the head and neck are most commonly managed by surgery, radiotherapy, or combined-modality therapy. for combined-modality cases, the sequencing of surgery and radiotherapy is generally guided by which modality is consi

Head and neck mucosal melanoma: Experien

Head and neck mucosal melanoma: Experience with 42 patients, with emphasis on the role of postoperative radiotherapy

✍ Marco Meleti; C. René Leemans; Remco de Bree; Paolo Vescovi; Enrico Sesenna; Isa 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB 👁 1 views

## Abstract ## Background. Treatment of head and neck mucosal melanoma remains a challenge. Surgery has traditionally been the main therapeutic approach. The role of postoperative radiotherapy has never been clearly established. ## Methods. The experience with a group of 42 patients (16 males, 2

Polaprezinc prevents oral mucositis asso

Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer

✍ Tomoko Watanabe; Masashi Ishihara; Katsuhiko Matsuura; Keisuke Mizuta; Yoshinori 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 192 KB 👁 1 views

## Abstract Oral mucositis is frequent but serious adverse event associated with radiotherapy or radiochemotherapy in head and neck cancer severely impairs health‐related quality of life, leading to poor prognosis due to discontinuation of the therapy. Although a number of compounds have been teste

Malignant mucosal melanoma of the head a

Malignant mucosal melanoma of the head and neck : Review of the literature and report of 14 patients

✍ Spiros Manolidis; Paul J. Donald 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 2 views

local and distant metastasis of the disease. Over 1000 patients with this disease setts. have been reported. Survivals at 5 and 10 years is 17% and 5%, respectively. Approximately 19% of patients present with lymph node metastasis and another 16%

Neck dissection in the combined-modality

Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer

✍ Athanassios Argiris; Kerstin M. Stenson; Bruce E. Brockstein; Bharat B. Mittal; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB 👁 2 views

## Abstract ## Purpose. The purpose of this study was to evaluate the role of neck lymph node (ND) in the combined dissection modality therapy for locoregionally advanced head and neck. ## Methods. We identified patients with N2–N3 head and neck cancers who were enrolled in three consecutive mul